Notice: This company has been marked as potentially delisted and may not be actively trading. Auris Medical (EARS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends EARS vs. UBX, SPRB, BFRG, MEIP, NRBO, TNXP, PRPH, APRE, NNVC, and CARAShould you be buying Auris Medical stock or one of its competitors? The main competitors of Auris Medical include Unity Biotechnology (UBX), Spruce Biosciences (SPRB), Bullfrog AI (BFRG), MEI Pharma (MEIP), NeuroBo Pharmaceuticals (NRBO), Tonix Pharmaceuticals (TNXP), ProPhase Labs (PRPH), Aprea Therapeutics (APRE), NanoViricides (NNVC), and Cara Therapeutics (CARA). These companies are all part of the "medical" sector. Auris Medical vs. Unity Biotechnology Spruce Biosciences Bullfrog AI MEI Pharma NeuroBo Pharmaceuticals Tonix Pharmaceuticals ProPhase Labs Aprea Therapeutics NanoViricides Cara Therapeutics Auris Medical (NASDAQ:EARS) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Is EARS or UBX more profitable? Auris Medical's return on equity of 0.00% beat Unity Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Auris MedicalN/A N/A N/A Unity Biotechnology N/A -119.70%-45.86% Which has more volatility & risk, EARS or UBX? Auris Medical has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Unity Biotechnology has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Do analysts recommend EARS or UBX? Unity Biotechnology has a consensus price target of $8.00, indicating a potential upside of 589.66%. Given Unity Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Unity Biotechnology is more favorable than Auris Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Auris Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Unity Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor EARS or UBX? Auris Medical received 242 more outperform votes than Unity Biotechnology when rated by MarketBeat users. However, 66.54% of users gave Unity Biotechnology an outperform vote while only 55.67% of users gave Auris Medical an outperform vote. CompanyUnderperformOutperformAuris MedicalOutperform Votes41755.67% Underperform Votes33244.33% Unity BiotechnologyOutperform Votes17566.54% Underperform Votes8833.46% Do insiders and institutionals believe in EARS or UBX? 6.0% of Auris Medical shares are owned by institutional investors. Comparatively, 29.5% of Unity Biotechnology shares are owned by institutional investors. 5.8% of Unity Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, EARS or UBX? Auris Medical has higher earnings, but lower revenue than Unity Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAuris MedicalN/AN/A-$8.75MN/AN/AUnity Biotechnology$240K81.44-$39.86M-$1.31-0.89 Does the media refer more to EARS or UBX? In the previous week, Auris Medical's average media sentiment score of 0.05 beat Unity Biotechnology's score of 0.00 indicating that Auris Medical is being referred to more favorably in the media. Company Overall Sentiment Auris Medical Neutral Unity Biotechnology Neutral SummaryUnity Biotechnology beats Auris Medical on 7 of the 13 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Auris Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EARS vs. The Competition Export to ExcelMetricAuris MedicalPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.92M$6.42B$5.00B$8.84BDividend YieldN/A8.11%7.72%4.07%P/E RatioN/A5.7282.7914.75Price / SalesN/A383.001,398.1588.44Price / CashN/A22.1633.2232.45Price / Book0.275.404.664.65Net Income-$8.75M$152.87M$117.62M$224.84M Auris Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EARSAuris MedicalN/A$0.43-4.4%N/A+54.0%$4.92MN/A0.00132,200Analyst ForecastUBXUnity Biotechnology3.7788 of 5 stars$1.21-4.0%N/A-44.1%$20.39M$240,000.00-0.9260Positive NewsSPRBSpruce Biosciences3.4446 of 5 stars$0.49-5.8%N/A-64.9%$20.26M$10.09M-0.5220BFRGBullfrog AI1.0291 of 5 stars$2.28+0.4%N/A-30.5%$19.87M$60,000.00-2.684MEIPMEI Pharma4.2167 of 5 stars$2.92-3.0%N/A-52.2%$19.46M$65.30M-0.42100Earnings ReportNews CoverageNRBONeuroBo Pharmaceuticals3.3068 of 5 stars$2.22-7.1%N/A-34.1%$19.13MN/A0.008News CoverageTNXPTonix Pharmaceuticals3.0059 of 5 stars$0.13-7.1%N/A-99.1%$17.99M$7.77M0.00103Earnings ReportNews CoveragePRPHProPhase Labs3.3064 of 5 stars$0.75flatN/A-82.2%$17.91M$44.38M-0.60130Gap DownAPREAprea Therapeutics3.3772 of 5 stars$3.25-3.0%N/A-21.0%$17.66M$580,000.00-1.167Analyst ForecastGap UpNNVCNanoViricidesN/A$1.23-8.2%N/A+16.8%$17.15MN/A-1.6220Analyst DowngradeGap UpCARACara Therapeutics3.8685 of 5 stars$0.31-6.0%N/A-73.4%$17.06M$20.97M-0.1855Gap Down Related Companies and Tools Related Companies UBX Alternatives SPRB Alternatives BFRG Alternatives MEIP Alternatives NRBO Alternatives TNXP Alternatives PRPH Alternatives APRE Alternatives NNVC Alternatives CARA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EARS) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Auris Medical Holding Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Auris Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EARS Stock Alerts